Form 4: SoftBank Affiliates Sell Vir Biotechnology Shares

Affiliates of SoftBank Vision Fund, a 10% owner and director, sold over 29,000 shares of Vir Biotechnology common stock in pre-arranged transactions.

Summary

• SVF Endurance (Cayman) Ltd, an affiliate of SoftBank Vision Fund, disposed of 29,515 shares of Vir Biotechnology, Inc. common stock across two transactions.
• On October 15, 2025, 16,671 shares were sold at a weighted average price of $6.0702 per share.
• On October 16, 2025, an additional 12,844 shares were sold at a weighted average price of $6.1014 per share.
• These sales were executed pursuant to a Rule 10b5-1 trading plan established by the Reporting Person on September 3, 2025.
• Following these transactions, the indirect beneficial ownership of SVF Endurance (Cayman) Ltd in Vir Biotechnology, Inc. stands at 15,340,494 shares.
• The reporting persons, including SVF Endurance (Cayman) Ltd, SoftBank Vision Fund (AIV M1) L.P., and SB Investment Advisers (UK) Ltd, are identified as 10% owners and directors of Vir Biotechnology, Inc.

Sentiment

Score: 4

Explanation: The sale of shares by a significant insider is generally a negative signal. However, the execution under a Rule 10b5-1 plan mitigates the negative sentiment, as it indicates a pre-scheduled transaction rather than one based on immediate, non-public information, making the overall sentiment slightly negative to neutral.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, which suggests the transactions were not based on new, non-public information and were scheduled in advance for purposes such as diversification or liquidity.

Negatives

• A significant sale of shares by a 10% owner and director, even under a 10b5-1 plan, can be perceived by the market as a reduction in confidence or a signal of limited upside potential.

Risks

• The market may interpret the insider selling as a negative signal, potentially leading to downward pressure on Vir Biotechnology's stock price.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing reports an insider transaction and does not provide information directly related to broader industry trends or competitive landscape within the biotechnology sector.

Related Party Transactions

• The reported sales of common stock by SVF Endurance (Cayman) Ltd, an affiliate of SoftBank Vision Fund, constitute related party transactions as the reporting persons are 10% owners and directors of Vir Biotechnology, Inc.

Stakeholder Impact

• Shareholders may view the sale by a significant owner and director as a potential signal of reduced confidence in the company's near-term prospects, despite the 10b5-1 plan.
• The transaction could lead to increased scrutiny from investors regarding the company's valuation and future growth trajectory.

Key Dates

Recommendation

The sale of shares by a 10% owner and director, even under a Rule 10b5-1 plan, is not typically a strong positive signal. While the pre-arranged nature of the sale reduces the immediate negative implication of insider selling, it does not provide a compelling reason to buy. Conversely, it's not a strong enough signal for an immediate sell recommendation without further fundamental analysis. Therefore, a 'hold' recommendation is appropriate, suggesting investors maintain their current position while monitoring future developments.

Keywords

Vir Biotechnology, VIR, SoftBank, SVF Endurance, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Biotechnology, Equity Disposition